Company profile
FATE THERAPEUTICS INC
NASDAQ:FATEBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FT-516 | phase1 | — | 2 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (23)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06308978 | phase1 | recruiting | 2024-03-28 | 2027-09-30 | Fate Therapeutics | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease |
| NCT02354417 | phase1 | terminated | 2014-12-01 | 2016-12-01 | Fate Therapeutics | A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies |
| NCT07570862 | phase2 | recruiting | 2026-07-27 | 2029-07-01 | Fate Therapeutics | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis |
| NCT02354443 | phase1 | terminated | 2015-06-01 | 2016-12-01 | Fate Therapeutics | A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders |
| NCT03319459 | phase1 | completed | 2018-01-18 | 2020-05-29 | Fate Therapeutics | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors |
FDA applications (0)
No records yet.